Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?

Ageing Research Reviews

Volumn 10, Issue 2, 2011, Pages 264-273

  Correia, Sónia C ^a,b   Santos, Renato X ^a,b   Perry, George ^c,d   Zhu, Xiongwei ^c   IMoreira, Paula ^a,e   Smith, Mark A ^c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^e UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Alzheimer's disease; Glucose metabolism; Insulin signaling; Streptozotocin

Indexed keywords

AMYLOID BETA PROTEIN; GLUCOSE; INSULIN; STREPTOZOCIN;

ALZHEIMER DISEASE; BEHAVIOR CHANGE; BRAIN DYSFUNCTION; BRAIN FUNCTION; ENERGY METABOLISM; ENZYME DEGRADATION; GLUCOSE BRAIN LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; SPORADIC ALZHEIMER DISEASE;

ALZHEIMER DISEASE; ANIMALS; BLOOD GLUCOSE; BRAIN; DIABETES MELLITUS, EXPERIMENTAL; ENERGY METABOLISM; INJECTIONS, INTRAVENTRICULAR; INSULIN; OXIDATIVE STRESS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STREPTOZOCIN;

RATTUS;

EID: 79952449386     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2011.01.001     Document Type: Review

References (159)

1. Adamo M., Raizada M.K., LeRoith D. Insulin and insulin-like growth factor receptors in the nervous system. Mol. Neurobiol. 1989, 3:71-100.
2. Agrawal R., Tyagi E., Shukla R., Nath C. A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia. Neuropharmacology 2009, 56:779-787.
3. Arluison M., Quignon M., Nguyen P., Thorens B., Leloup C., Penicaud L. Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain-an immunohistochemical study. J. Chem. Neuroanat. 2004, 28:117-136.
4. Arluison M., Quignon M., Thorens B., Leloup C., Penicaud L. Immunocytochemical localization of the glucose transporter 2 (GLUT2) in the adult rat brain. II. Electron microscopic study. J. Chem. Neuroanat. 2004, 28:137-146.
5. Azari N.P., Pettigrew K.D., Schapiro M.B., Haxby J.V., Grady C.L., Pietrini P., Salerno J.A., Heston L.L., Rapoport S.I., Horwitz B. Early detection of Alzheimer's disease: a statistical approach using positron emission tomographic data. J. Cereb. Blood Flow Metab. 1993, 13:438-447.
6. Banks W.A. The source of cerebral insulin. Eur. J. Pharmacol. 2004, 490:5-12.
7. Baskin D.S., Browning J.L., Pirozzolo F.J., Korporaal S., Baskin J.A., Appel S.H. Brain choline acetyltransferase and mental function in Alzheimer disease. Arch. Neurol. 1999, 56:1121-1123.
8. Bhat N.R. Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators. J. Neurochem. 2010, 115:551-562.
9. Blokland A., Jolles J. Spatial learning deficit and reduced hippocampal ChAT activity in rats after an ICV injection of streptozotocin. Pharmacol. Biochem. Behav. 1993, 44:491-494.
10. Blokland A., Jolles J. Behavioral and biochemical effects of an ICV injection of streptozotocin in old Lewis rats. Pharmacol. Biochem. Behav. 1994, 47:833-837.
11. Bosetti F., Brizzi F., Barogi S., Mancuso M., Siciliano G., Tendi E.A., Murri L., Rapoport S.I., Solaini G. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol. Aging 2002, 23:371-376.
12. Bryant N.J., Govers R., James D.E. Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell Biol. 2002, 3:267-277.
13. Bubber P., Haroutunian V., Fisch G., Blass J.P., Gibson G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 2005, 57:695-703.
14. Buee L., Hof P.R., Bouras C., Delacourte A., Perl D.P., Morrison J.H., Fillit H.M. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol. 1994, 87:469-480.
15. Burns J.M., Donnelly J.E., Anderson H.S., Mayo M.S., Spencer-Gardner L., Thomas G., Cronk B.B., Haddad Z., Klima D., Hansen D., Brooks W.M. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 2007, 69:1094-1104.
16. Cao D., Lu H., Lewis T.L., Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 2007, 282:36275-36282.
17. Cardoso S., Correia S., Santos R.X., Carvalho C., Santos M.S., Oliveira C.R., Perry G., Smith M.A., Zhu X., Moreira P.I. Insulin is a two-edged knife on the brain. J. Alzheimers Dis 2009, 18:483-507.
18. Castellani R.J., Harris P.L., Sayre L.M., Fujii J., Taniguchi N., Vitek M.P., Founds H., Atwood C.S., Perry G., Smith M.A. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med. 2001, 31:175-180.
19. Cheng C.M., Tseng V., Wang J., Wang D., Matyakhina L., Bondy C.A. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 2005, 146:5086-5091.
20. Cole G.M., Frautschy S.A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp. Gerontol. 2007, 42:10-21.
21. Craft S., Asthana S., Newcomer J.W., Wilkinson C.W., Matos I.T., Baker L.D., Cherrier M., Lofgreen C., Latendresse S., Petrova A., Plymate S., Raskind M., Grimwood K., Veith R.C. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry 1999, 56:1135-1140.
22. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
23. Czech M.P., Corvera S. Signaling mechanisms that regulate glucose transport. J. Biol. Chem. 1999, 274:1865-1868.
24. Davis S., Laroche S. Mitogen-activated protein kinase/extracellular regulated kinase signalling and memory stabilization: a review. Genes, Brain, Behavior 2006, 5(Suppl. 2):61-72.
25. de la Monte S.M., Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis. 2005, 7:45-61.
26. de la Monte S.M., Wands J.R. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis. 2006, 9:167-181.
27. de la Monte S.M., Tong M., Lester-Coll N., Plater M., Wands J.R. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimers Dis. 2006, 10:89-109.
28. Deng Y., Li B., Liu Y., Iqbal K., Grundke-Iqbal I., Gong C.X. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer's disease. Am. J. Pathol. 2009, 175:2089-2098.
29. Devaskar S.U., Giddings S.J., Rajakumar P.A., Carnaghi L.R., Menon R.K., Zahm D.S. Insulin gene expression and insulin synthesis in mammalian neuronal cells. J. Biol. Chem. 1994, 269:8445-8454.
30. Doreulee N., Sergeeva O.A., Yanovsky Y., Chepkova A.N., Selbach O., Godecke A., Schrader J., Haas H.L. Cortico-striatal synaptic plasticity in endothelial nitric oxide synthase deficient mice. Brain Res. 2003, 964:159-163.
31. Droge W., Kinscherf R. Aberrant insulin receptor signaling and amino acid homeostasis as a major cause of oxidative stress in aging. Antioxid. Redox Signal. 2008, 10:661-678.
32. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997, 275:661-665.
33. Duelli R., Schrock H., Kuschinsky W., Hoyer S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int. J. Dev. Neurosci. 1994, 12:737-743.
34. Eckel-Mahan K.L., Phan T., Han S., Wang H., Chan G.C., Scheiner Z.S., Storm D.R. Circadian oscillation of hippocampal MAPK activity and cAmp: implications for memory persistence. Nat. Neurosci. 2008, 11:1074-1082.
35. Elsner M., Guldbakke B., Tiedge M., Munday R., Lenzen S. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 2000, 43:1528-1533.
36. English J.D., Sweatt J.D. Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation. J. Biol. Chem. 1996, 271:24329-24332.
37. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J. Alzheimers Dis. 2008, 13:241-253.
38. Frolich L., Blum-Degen D., Bernstein H.G., Engelsberger S., Humrich J., Laufer S., Muschner D., Thalheimer A., Turk A., Hoyer S., Zochling R., Boissl K.W., Jellinger K., Riederer P. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J. Neural Transm. 1998, 105:423-438.
39. Frolich L., Blum-Degen D., Riederer P., Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann. N. Y. Acad. Sci. 1999, 893:290-293.
40. Games D., Buttini M., Kobayashi D., Schenk D., Seubert P. Mice as models: transgenic approaches and Alzheimer's disease. J. Alzheimers Dis. 2006, 9:133-149.
41. Gasparini L., Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 2003, 26:404-406.
42. Gasparini L., Gouras G.K., Wang R., Gross R.S., Beal M.F., Greengard P., Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 2001, 21:2561-2570.
43. Gimenez-Llort L., Schiffmann S.N., Shmidt T., Canela L., Camon L., Wassholm M., Canals M., Terasmaa A., Fernandez-Teruel A., Tobena A., Popova E., Ferre S., Agnati L., Ciruela F., Martinez E., Scheel-Kruger J., Lluis C., Franco R., Fuxe K., Bader M. Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiol. Learn. Mem. 2007, 87:42-56.
44. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
45. Grieb P., Kryczka T., Fiedorowicz M., Frontczak-Baniewicz M., Walski M. Expansion of the Golgi apparatus in rat cerebral cortex following intracerebroventricular injections of streptozotocin. Acta Neurobiol. Exp. (Wars) 2004, 64:481-489.
46. Grunblatt E., Koutsilieri E., Hoyer S., Riederer P. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. J. Alzheimers Dis. 2006, 9:261-271.
47. Grunblatt E., Salkovic-Petrisic M., Osmanovic J., Riederer P., Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J. Neurochem. 2007, 101:757-770.
48. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
49. Havrankova J., Roth J., Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978, 272:827-829.
50. Hellweg R., Nitsch R., Hock C., Jaksch M., Hoyer S. Nerve growth factor and choline acetyltransferase activity levels in the rat brain following experimental impairment of cerebral glucose and energy metabolism. J. Neurosci. Res. 1992, 31:479-486.
51. Henneberg N., Hoyer S. Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)?. Arch. Gerontol. Geriatr. 1995, 21:63-74.
52. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., Smith M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001, 21:3017-3023.
53. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004, 18:902-904.
54. Hong M., Lee V.M. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 1997, 272:19547-19553.
55. Hoyer S. Risk factors for Alzheimer's disease during aging. Impacts of glucose/energy metabolism. J. Neural Transm. Suppl. 1998, 54:187-194.
56. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J. Neural Transm. 2002, 109:341-360.
57. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv. Exp. Med. Biol. 2004, 541:135-152.
58. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 2004, 490:115-125.
59. Hoyer S., Lannert H. Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats. Ann. N. Y. Acad. Sci. 1999, 893:301-303.
60. Hoyer S., Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J. Neural Transm. 1989, 75:227-232.
61. Huang H.M., Ou H.C., Xu H., Chen H.L., Fowler C., Gibson G.E. Inhibition of alpha-ketoglutarate dehydrogenase complex promotes cytochrome c release from mitochondria, caspase-3 activation, and necrotic cell death. J. Neurosci. Res. 2003, 74:309-317.
62. Ishiguro K., Shiratsuchi A., Sato S., Omori A., Arioka M., Kobayashi S., Uchida T., Imahori K. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 1993, 325:167-172.
63. Ishrat T., Khan M.B., Hoda M.N., Yousuf S., Ahmad M., Ansari M.A., Ahmad A.S., Islam F. Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. Behav. Brain Res. 2006, 171:9-16.
64. Johnston A.M., Pirola L., Van Obberghen E. Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signalling. FEBS Lett. 2003, 546:32-36.
65. Joseph J., Shukitt-Hale B., Denisova N.A., Martin A., Perry G., Smith M.A. Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol. Aging 2001, 22:131-146.
66. Kahn C.R., White M.F. The insulin receptor and the molecular mechanism of insulin action. J. Clin. Invest. 1988, 82:1151-1156.
67. Katakam P.V., Domoki F., Lenti L., Gaspar T., Institoris A., Snipes J.A., Busija D.W. Cerebrovascular responses to insulin in rats. J. Cereb. Blood Flow Metab. 2009, 29:1955-1967.
68. Katakam P.V., Domoki F., Snipes J.A., Busija A.R., Jarajapu Y.P., Busija D.W. Impaired mitochondria-dependent vasodilation in cerebral arteries of Zucker obese rats with insulin resistance. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R289-298.
69. Kidd M. Alzheimer's disease-an electron microscopical study. Brain 1964, 87:307-320.
70. Kish S.J., Bergeron C., Rajput A., Dozic S., Mastrogiacomo F., Chang L.J., Wilson J.M., DiStefano L.M., Nobrega J.N. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 1992, 59:776-779.
71. Lannert H., Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 1998, 112:1199-1208.
72. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Wittorf A., Richartz E., Bartels M., Buchkremer G., Schott K. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J. Neural Transm. 2006, 113:1217-1224.
73. Lee J., Fukumoto H., Orne J., Klucken J., Raju S., Vanderburg C.R., Irizarry M.C., Hyman B.T., Ingelsson M. Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp. Neurol. 2005, 194:91-96.
74. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., Selkoe D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093.
75. Lester-Coll N., Rivera E.J., Soscia S.J., Doiron K., Wands J.R., de la Monte S.M. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimers Dis. 2006, 9:13-33.
76. Li L., Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 2007, 56:384-402.
77. Liu Y., Liu F., Iqbal K., Grundke-Iqbal I., Gong C.X. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 2008, 582:359-364.
78. Lizcano J.M., Alessi D.R. The insulin signalling pathway. Curr. Biol. 2002, 12:R236-R238.
79. Lopez-Lopez C., Dietrich M.O., Metzger F., Loetscher H., Torres-Aleman I. Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. J. Neurosci. 2007, 27:824-831.
80. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001, 20:27-39.
81. Luse S.A., Smith K.R. The ultrastructure of senile plaques. Am. J. Pathol. 1964, 44:553-563.
82. Man H.Y., Lin J.W., Ju W.H., Ahmadian G., Liu L., Becker L.E., Sheng M., Wang Y.T. Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. Neuron 2000, 25:649-662.
83. Margolis R.U., Altszuler N. Insulin in the cerebrospinal fluid. Nature 1967, 215:1375-1376.
84. Mattson M.P., Gary D.S., Chan S.L., Duan W. Perturbed endoplasmic reticulum function, synaptic apoptosis and the pathogenesis of Alzheimer's disease. Biochem. Soc. Symp. 2001, 151-162.
85. McEwen B.S., Reagan L.P. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur. J. Pharmacol. 2004, 490:13-24.
86. McGeer P.L., McGeer E.G., Suzuki J., Dolman C.E., Nagai T. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology 1984, 34:741-745.
87. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31:224-243.
88. Montagnani M., Chen H., Barr V.A., Quon M.J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J. Biol. Chem. 2001, 276:30392-30398.
89. Moreira P.I., Honda K., Zhu X., Nunomura A., Casadesus G., Smith M.A., Perry G. Brain and brawn: parallels in oxidative strength. Neurology 2006, 66:S97-S101.
90. Moreira P.I., Harris P.L., Zhu X., Santos M.S., Oliveira C.R., Smith M.A., Perry G. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J. Alzheimers Dis. 2007, 12:195-206.
91. Moreira P.I., Santos M.S., Oliveira C.R. Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid. Redox Signal. 2007, 9:1621-1630.
92. Moreira P.I., Santos M.S., Seica R., Oliveira C.R. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J. Neurol. Sci. 2007, 257:206-214.
93. Moreira P.I., Duarte A.I., Santos M.S., Rego A.C., Oliveira C.R. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J. Alzheimers Dis. 2009, 16:741-761.
94. Nitsch R., Hoyer S. Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci. Lett. 1991, 128:199-202.
95. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., Smith M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 1999, 19:1959-1964.
96. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
97. Park C.R. Cognitive effects of insulin in the central nervous system. Neurosci. Biobehav. Rev. 2001, 25:311-323.
98. Parker W.D., Mahr N.J., Filley C.M., Parks J.K., Hughes D., Young D.A., Cullum C.M. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 1994, 44:1086-1090.
99. Pathan A.R., Viswanad B., Sonkusare S.K., Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 2006, 79:2209-2216.
100. Paz K., Voliovitch H., Hadari Y.R., Roberts C.T., LeRoith D., Zick Y. Interaction between the insulin receptor and its downstream effectors. Use of individually expressed receptor domains for structure/function analysis. J. Biol. Chem. 1996, 271:6998-7003.
101. Pei J.J., Khatoon S., An W.L., Nordlinder M., Tanaka T., Braak H., Tsujio I., Takeda M., Alafuzoff I., Winblad B., Cowburn R.F., Grundke-Iqbal I., Iqbal K. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol 2003, 105:381-392.
102. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
103. Plaschke K., Hoyer S. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int. J. Dev. Neurosci. 1993, 11:477-483.
104. Plaschke K., Kopitz J., Siegelin M., Schliebs R., Salkovic-Petrisic M., Riederer P., Hoyer S. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J. Alzheimers Dis. 2010, 19:691-704.
105. Prickaerts J., Fahrig T., Blokland A. Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v. injection of streptozotocin: a correlation analysis. Behav. Brain Res. 1999, 102:73-88.
106. Prickaerts J., De Vente J., Honig W., Steinbusch H., Ittersum M.M.V., Blokland A., Steinbusch H.W. Nitric oxide synthase does not mediate neurotoxicity after an i.c.v. injection of streptozotocin in the rat. J. Neural Transm. 2000, 107:745-766.
107. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 1998, 273:32730-32738.
108. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
109. Rapoport S.I. Coupled reductions in brain oxidative phosphorylation and synaptic function can be quantified and staged in the course of Alzheimer disease. Neurotox. Res. 2003, 5:385-398.
110. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 2005, 8:247-268.
111. Rocchi A., Pellegrini S., Siciliano G., Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res. Bull. 2003, 61:1-24.
112. Rocchi A., Orsucci D., Tognoni G., Ceravolo R., Siciliano G. The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. Curr. Alzheimer Res. 2009, 6:224-237.
113. Salkovic-Petrisic M., Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J. Neural Transm. Suppl. 2007, 217-233.
114. Salkovic-Petrisic M., Tribl F., Schmidt M., Hoyer S., Riederer P. Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J. Neurochem. 2006, 96:1005-1015.
115. Saltiel A.R., Pessin J.E. Insulin signaling pathways in time and space. Trends Cell Biol. 2002, 12:65-71.
116. Santos M.S., Pereira E.M., Carvaho A.P. Stimulation of immunoreactive insulin release by glucose in rat brain synaptosomes. Neurochem. Res. 1999, 24:33-36.
117. Schechter R., Abboud M. Neuronal synthesized insulin roles on neural differentiation within fetal rat neuron cell cultures. Brain Res. Dev. Brain Res. 2001, 127:41-49.
118. Schechter R., Whitmire J., Holtzclaw L., George M., Harlow R., Devaskar S.U. Developmental regulation of insulin in the mammalian central nervous system. Brain Res. 1992, 582:27-37.
119. Schechter R., Beju D., Gaffney T., Schaefer F., Whetsell L. Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system. Brain Res. 1996, 736:16-27.
120. Scheepers A., Joost H.G., Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN. J. Parenter. Enteral Nutr. 2004, 28:364-371.
121. Schubert M., Gautam D., Surjo D., Ueki K., Baudler S., Schubert D., Kondo T., Alber J., Galldiks N., Kustermann E., Arndt S., Jacobs A.H., Krone W., Kahn C.R., Bruning J.C. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3100-3105.
122. Selkoe D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers Dis. 2001, 3:75-80.
123. Sharma M., Gupta Y.K. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci. 2001, 68:1021-1029.
124. Sharma M., Gupta Y.K. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci. 2002, 71:2489-2498.
125. Shoham S., Bejar C., Kovalev E., Weinstock M. Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp. Neurol. 2003, 184:1043-1052.
126. Shoham S., Bejar C., Kovalev E., Schorer-Apelbaum D., Weinstock M. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 2007, 52:836-843.
127. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung De Aburto M.A., Chen W., Czernin J., Rapoport S.I., Pietrini P., Alexander G.E., Schapiro M.B., Jagust W.J., Hoffman J.M., Welsh-Bohmer K.A., Alavi A., Clark C.M., Salmon E., de Leon M.J., Mielke R., Cummings J.L., Kowell A.P., Gambhir S.S., Hoh C.K., Phelps M.E. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001, 286:2120-2127.
128. Sims N.R., Bowen D.M., Allen S.J., Smith C.C., Neary D., Thomas D.J., Davison A.N. Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem. 1983, 40:503-509.
129. Skoog I. Vascular aspects in Alzheimer's disease. J. Neural Transm. Suppl. 2000, 59:37-43.
130. Small G.W., Komo S., La Rue A., Saxena S., Phelps M.E., Mazziotta J.C., Saunders A.M., Haines J.L., Pericak-Vance M.A., Roses A.D. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann. N. Y. Acad. Sci. 1996, 802:70-78.
131. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 1997, 17:2653-2657.
132. Solano D.C., Sironi M., Bonfini C., Solerte S.B., Govoni S., Racchi M. Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J. 2000, 14:1015-1022.
133. Sonkusare S., Srinivasan K., Kaul C., Ramarao P. Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci. 2005, 77:1-14.
134. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
135. Straface E., Matarrese P., Gambardella L., Vona R., Sgadari A., Silveri M.C., Malorni W. Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: a pilot study. FEBS Lett. 2005, 579:2759-2766.
136. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 2001, 50:537-546.
137. Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., Kurinami H., Shinohara M., Rakugi H., Morishita R. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7036-7041.
138. Tarkowski E., Issa R., Sjogren M., Wallin A., Blennow K., Tarkowski A., Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol. Aging 2002, 23:237-243.
139. Terry R.D., Gonatas N.K., Weiss M. Ultrastructural studies in Alzheimer's presenile dementia. Am. J. Pathol. 1964, 44:269-297.
140. Terwel D., Prickaerts J., Meng F., Jolles J. Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine. Eur. J. Pharmacol. 1995, 287:65-71.
141. Tota S., Awasthi H., Kamat P.K., Nath C., Hanif K. Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav. Brain Res. 2010, 209:73-79.
142. Tretter L., Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J. Neurosci. 2000, 20:8972-8979.
143. Unger J., McNeill T.H., Moxley R.T., White M., Moss A., Livingston J.N. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience 1989, 31:143-157.
144. Valla J., Schneider L., Niedzielko T., Coon K.D., Caselli R., Sabbagh M.N., Ahern G.L., Baxter L., Alexander G., Walker D.G., Reiman E.M. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 2006, 6:323-330.
145. van der Heide L.P., Ramakers G.M., Smidt M.P. Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol. 2006, 79:205-221.
146. Vannucci S.J., Maher F., Simpson I.A. Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia 1997, 21:2-21.
147. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., Selkoe D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 2000, 20:1657-1665.
148. Wan Q., Xiong Z.G., Man H.Y., Ackerley C.A., Braunton J., Lu W.Y., Becker L.E., MacDonald J.F., Wang Y.T. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature 1997, 388:686-690.
149. Wang B., Yang L., Wang Z., Zheng H. Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14140-14145.
150. Watson G.S., Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 2004, 490:97-113.
151. Watson G.S., Peskind E.R., Asthana S., Purganan K., Wait C., Chapman D., Schwartz M.W., Plymate S., Craft S. Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003, 60:1899-1903.
152. Weinstock M., Shoham S. Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J. Neural Transm. 2004, 111:347-366.
153. White M.F., Kahn C.R. The insulin signaling system. J. Biol. Chem. 1994, 269:1-4.
154. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215:1237-1239.
155. Wozniak M., Rydzewski B., Baker S.P., Raizada M.K. The cellular and physiological actions of insulin in the central nervous system. Neurochem. Int. 1993, 22:1-10.
156. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
157. Young W.S. Periventricular hypothalamic cells in the rat brain contain insulin mRNA. Neuropeptides 1986, 8:93-97.
158. Yu S., Ding W.G. The 45 kDa form of glucose transporter 1 (GLUT1) is localized in oligodendrocyte and astrocyte but not in microglia in the rat brain. Brain Res. 1998, 797:65-72.
159. Zhao W.Q., Chen H., Quon M.J., Alkon D.L. Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 2004, 490:71-81.